Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Mindset Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Biotech Announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"University of Sydney","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Announces Private Placement and Concurrent Debt Settlement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Closes Private Placement and Concurrent Debt Settlement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by PharmAla Biotech

    Menu

    PharmAla Biotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PharmAla Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmAla Closes Private Placement and Concurrent Debt Settlement

              Details:

              The net proceeds will be used for the development of company's portfolio of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine), which is under investigation for the treatment of PTSD and social anxiety in autistic adults.

              Lead Product(s): Midomafetamine

              Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $0.7 million Upfront Cash: Undisclosed

              Deal Type: Private Placement April 19, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAla Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmAla Announces Private Placement and Concurrent Debt Settlement

              Details:

              The net proceeds will be used for the development of company's portfolio of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine), which is under investigation for the treatment of PTSD and social anxiety in autistic adults.

              Lead Product(s): Midomafetamine

              Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $0.7 million Upfront Cash: Undisclosed

              Deal Type: Private Placement April 10, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAla Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney

              Details:

              The agreement aims for the clinical phase development of ALA-002 which under investigation for the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autistic adults.

              Lead Product(s): ALA-002

              Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: University of Sydney

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAla Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmAla Biotech Announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000

              Details:

              The Company intends to use the net proceeds to fund phase 2 clinical trials of the Company’s patented ALA series of molecules including, ALA-002, an oral, small molecule drug being developed for the treatment of social anxiety disorder and post-traumatic stress disorder.

              Lead Product(s): ALA-002

              Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $5.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement June 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAla Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

              Details:

              Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.

              Lead Product(s): Psilocybine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAla Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin

              Details:

              Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP (i.e. pharmaceutical grade) psilocybin to appropriately licensed clinical researchers.

              Lead Product(s): Psilocybine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Mindset Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmAla Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

              Details:

              PharmAla’s goal is to bring ALA-002 into the clinic as a treatment for disorders in adults diagnosed with Autism Spectrum Disorder (ASD). ALA-002 was tested not only in general population research, but also in generally accepted autism mouse models.

              Lead Product(s): ALA-002

              Therapeutic Area: Neurology Product Name: ALA-002

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY